Dogwood Therapeutics Inc
dwtx.comDogwood Therapeutics Inc (NASDAQ: DWTX) is a clinical-stage biopharmaceutical company that develops drug candidates through FDA-regulated clinical trial programs. The company generates no product revenue and funds operations through equity issuances, including proceeds from an at-the-money equity distribution agreement executed November 28, 2025, and from preferred stock conversions. In September 2025, Dogwood entered an exclusive license agreement with Serpin Pharma, Inc., acquiring rights to additional drug candidates in exchange for equity consideration under an Equity Issuance and Registration Rights Agreement with Serpin Pharma and Rejuvenation Labs. The company traces its history through predecessor entities including Virios Therapeutics and Innovative Med Concepts, which held a know-how license from the University of Alabama dating to June 1, 2012. As of the 10-K filed March 18, 2026, Dogwood carries accumulated net losses and relies on capital markets for liquidity, with research and development expenses and general and administrative costs representing its primary cash outlays.
Products & Services
Drug candidates in clinical development subject to FDA Phase 1, Phase 2, and Phase 3 trial requirements, NDA submission, and post-approval compliance obligations. Licensed technology from Serpin Pharma under an exclusive license agreement dated September 29, 2025. Legacy know-how license from the University of Alabama, originally dated June 1, 2012.
Revenue Model
No product revenue as of the 10-K filed March 18, 2026. Operations are funded through equity issuances, including an at-the-money equity distribution agreement dated November 28, 2025, and preferred stock-to-common-stock conversions. Future revenue, if any, would depend on FDA approval and commercialization of drug candidates.
Customers & Markets
No commercial customers as of the 10-K filed March 18, 2026. Target end markets, if products reach commercialization, would be subject to Medicare, Medicaid, and third-party payor reimbursement dynamics in the United States and price control mechanisms in international markets.
Geographic Exposure
Primary regulatory focus on the United States FDA pathway. Filing references potential international commercialization subject to EEA data exclusivity rules and foreign price controls, but no disclosed international operations as of the 10-K filed March 18, 2026.
Financial Snapshot
Loading...
